Preliminary study on the effect of nucleolin specific aptamer–miRNA let-7d chimera on Janus kinase-2 expression level and activity in gastric cancer (MKN-45) cells
Recently, much attention has been focused on the use of miRNAs in cancer treatment. The role of proto-oncogene Janus kinase-2 (JAK-2) in proliferation and survival of gastric cancer has been previously documented. The aim of this study was to evaluate the effect of a chimera consisted of nucleolin specific aptamer (NCL-Apt) and miRNA let-7d on JAK2 expression level and activity in gastric cancer cells. NCL-Apt–miRNA let-7d chimera was prepared by two methods. Gastric cancer (MKN-45) cell line and control cell line of human dermal fibroblast (HDF) were treated with the chimera and the changes in JAK2 expression and activity were determined using real-time PCR and ELISA techniques, respectively. In MKN-45 cells, the chimera caused significant decrease in JAK2 expression level and activity compared to the aptamer alone and miRNA mimic negative control. Nevertheless, transfected miRNA let-7d showed remarkable reduction in the expression level of JAK2 in comparison with control state in both MKN-45 and HDF, confirmed unspecific effect of let-7d on normal and cancerous cells. With regard to the synergic effect of this chimera on JAK2 activity, it might be viewed as a therapeutic candidate in gastric cancer. However, further studies are warranted to prove it.
KeywordsNucleolin specific aptamer (NCL-Apt) MiRNA let-7d Janus kinase-2 (JAK-2) Gastric cancer
Human dermal fibroblasts
High-mobility group AT-hook 2
Platelet-derived growth factor receptor β
Signal transducer and activator of transcription 3
The three prime untranslated regions
This study was performed as an MSc thesis at Faculty of Paramedicene, Guilan University of Medical Sciences (Rasht, Iran). This work was financially supported by the Research Deputy of Guilan University of Medical Sciences (Rasht, Iran) and Shahid Beheshti University of Medical Sciences (Tehran, Iran).
Compliance with ethical standards
Conflict of interest
The authors declared that there are no conflict of interest.
- 2.Khademloo M, Moosazadeh M, Ahmadi M, Alizadeh-Navaei R (2018) Geographical distribution of gastric cancer in north of Iran—a cross-sectional study. World Cancer Res J 5(1):e1050Google Scholar
- 15.Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, Volinia S, Liu C-G, Schnittger S, Haferlach T (2008) Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 105(10):3945–3950CrossRefPubMedGoogle Scholar
- 21.Childs G, Fazzari M, Kung G, Kawachi N, Brandwein-Gensler M, McLemore M, Chen Q, Burk RD, Smith RV, Prystowsky MB (2009) Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol 174(3):736–745CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Di Fiore R, Drago-Ferrante R, Pentimalli F, Di Marzo D, Forte IM, Carlisi D, De Blasio A, Tesoriere G, Giordano A, Vento R (2016) Let-7d miRNA shows both antioncogenic and oncogenic functions in osteosarcoma-derived 3AB-OS cancer stem cells. J Cell Physiol 231(8):1832–1841CrossRefPubMedGoogle Scholar
- 30.Ramezanpour M, Daei P, Khanaki K, Hosseinabadi T, Tabarzad M (2017) The relationship between Janus kinase pathways and microRNAs. Trends Pept Protein Sci 1(4):144–152Google Scholar
- 41.Daei P, Ramezanpour M, Khanaki K, Tabarzad M, Nikokar I, Hedayati M, Elmi A (2018) Aptamer-based targeted delivery of miRNA let-7d to gastric cancer cells as a novel anti-tumor therapeutic agent. Iran J Pharm Sci 17(4):1537–1549Google Scholar
- 57.Esposito CL, Nuzzo S, Catuogno S, Romano S, de Nigris F, de Franciscis V (2017) STAT3 gene silencing by Aptamer-siRNA chimera as selective therapeutic for glioblastoma. Mol Ther-Nucleic Acids 10 398–411Google Scholar